Back to search results

A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer

IsraelRecruitingPHASE1

Conditions

Metastatic Castration-Resistant Prostate Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • City of Hope /ID# 262059, Duarte, California, United States

  • Univ California, San Francisco /ID# 261715, San Francisco, California, United States

  • Yale University School of Medicine /ID# 262234, New Haven, Connecticut, United States

  • AdventHealth Orlando /ID# 261686, Orlando, Florida, United States

  • University of Chicago Medical Center /ID# 261605, Chicago, Illinois, United States

  • START Midwest /ID# 264295, Grand Rapids, Michigan, United States

  • Carolina BioOncology Institute /ID# 261602, Huntersville, North Carolina, United States

  • Lifespan Cancer Institute at Rhode Island Hospital /ID# 261687, Providence, Rhode Island, United States

  • NEXT Oncology /ID# 261601, San Antonio, Texas, United States

  • Chris O'Brien Lifehouse /ID# 261731, Camperdown, New South Wales, Australia

  • Ballarat Base Hospital /ID# 264294, Ballarat, Victoria, Australia

  • St Vincent's Hospital /ID# 264293, Fitzroy, Victoria, Australia

  • Centre Hospitalier de l'Universite de Montreal (CHUM) /ID# 270890, Montreal, Quebec, Canada

  • McGill University Health Centre - Glen Site. /ID# 271275, Montreal, Quebec, Canada

  • Centre Oscar Lambret /ID# 270602, Lille, Nord, France

  • Centre Leon Berard /ID# 270605, Lyon, Rhone, France

  • Institut Gustave Roussy /ID# 270603, Villejuif, Île-de-France Region, France

    Study coordinator · +33-142-114322

  • The Chaim Sheba Medical Center /ID# 261772, Ramat Gan, Tel Aviv, Israel

  • Rambam Health Care Campus- Haifa /ID# 261770, Haifa, Israel

  • Hadassah Medical Center-Hebrew University /ID# 261771, Jerusalem, Israel

  • National Cancer Center Hospital East /ID# 261606, Kashiwa-shi, Chiba, Japan

  • Kyoto University Hospital /ID# 261861, Kyoto, Kyoto, Japan

  • National Cancer Center Hospital /ID# 261698, Chuo-ku, Tokyo, Japan

  • Hospital Universitario Vall de Hebron /ID# 270889, Barcelona, Spain

  • Hospital Universitario HM Sanchinarro /ID# 271345, Madrid, Spain

  • Hospital Universitario Virgen del Rocio /ID# 270617, Seville, Spain

Study leads

  • ABBVIE INC.

    Study Director

    AbbVie

View source on ClinicalTrials.gov(opens in a new tab)Contact study team (email)